NWBO stock forecast, quote, news & analysis

Key Takeaways

• Northwest Biotherapeutics (NWBO) trades near $0.18 per share on the OTCQB, within a 52-week range of roughly $0.14 to $0.37, after a modest, single-digit move over the trailing 30 days.
• The company's core asset is DCVax-L, a personalized dendritic-cell therapy that completed a 331-patient Phase III trial in glioblastoma (GBM) and was published in JAMA Oncology.
• Recent catalysts include a memorandum of understanding (MOU) with Saudi pharmaceutical group SPIMACO, updated Phase III survival analyses, and continued buildout of U.K. manufacturing capacity.
• The company reported a second-quarter 2026 net loss of approximately $17.9 million, reflecting its pre-revenue, development-stage profile.
• Key investor considerations center on U.K. regulatory review, funding, and commercialization execution.

Current Market Snapshot

Northwest Biotherapeutics is a micro-cap biotechnology company whose shares trade over the counter, well below the $1 threshold in the penny-stock range. In recent weeks the stock has fluctuated between roughly $0.16 and $0.19 per share, remaining range-bound and below its 52-week high of $0.3680 while holding above its 52-week low of $0.1411. Trading volume has periodically spiked around news releases, a pattern typical of development-stage biotech names where sentiment can shift quickly on clinical and partnership headlines. The broader oncology and cell-therapy sector remains an area of active investor interest, but sentiment toward pre-revenue issuers continues to be shaped by funding conditions and regulatory timelines.

Northwest Biotherapeutics (NWBO) Business Overview and Competitive Position

Founded in 1996 and headquartered in Bethesda, Maryland, Northwest Biotherapeutics develops personalized immune therapies for cancer built on its DCVax platform, which uses a patient's own activated dendritic cells to mobilize the immune system against solid tumors. Its lead candidate, DCVax-L, has completed a 331-patient international Phase III trial in newly diagnosed and recurrent glioblastoma, with results published in JAMA Oncology. The company has submitted a Marketing Authorization Application (MAA) for DCVax-L in the United Kingdom. Its pipeline also includes DCVax-Direct for inoperable solid tumors. Supporting the commercial path, the company has invested in proprietary manufacturing technology through subsidiary Flaskworks and expanded capacity at its Sawston, U.K. facility following the closing of its acquisition of Advent BioServices.

Recent Developments Driving NWBO

Several developments have shaped investor attention toward NWBO in recent months. In August 2026, the company announced a non-binding MOU with SPIMACO, one of Saudi Arabia's largest pharmaceutical manufacturers, to explore a collaboration bringing DCVax therapies into markets across the Middle East and North Africa. In July 2026, the company presented updated survival data from the DCVax-L Phase III glioblastoma trial using individual patient-level data in multiple independent analyses, arguing that the original survival benefit may have been underestimated. Earlier in the year, the company appointed Dr. Annalisa Jenkins, a seasoned biopharmaceutical executive, as a strategic adviser, and established a dedicated leukapheresis clinic in London to support the cell-collection step required for personalized therapy. On the financial side, Northwest Biotherapeutics reported a second-quarter 2026 net loss of about $17.9 million, consistent with a pre-commercial business still investing heavily in manufacturing and regulatory preparation.

Trending AI Robots

For traders seeking a systematic approach to markets like this, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots. Tickeron provides hundreds of AI trading bots that track thousands of tickers, yet only the top-performing and most relevant bots are featured in this section. These bots vary in strategy, timeframe, and performance metrics, giving users a way to compare different automated approaches to market timing and signal generation. The section is designed to help traders identify bots that align with their own objectives and risk tolerance. Exploring the Trending AI Robots page can be a useful starting point for investors interested in data-driven trading tools.

2026 Outlook and What Investors Should Watch

Looking ahead, the primary driver for NWBO is regulatory progress in the United Kingdom, where the DCVax-L marketing application is under review; any decision or milestone update could materially influence sentiment. Investors are also likely to monitor the progression of the SPIMACO collaboration from a non-binding MOU to a definitive agreement, the completion and validation of additional manufacturing capacity at the Sawston facility, and further presentations of DCVax-L clinical data. Financial considerations remain important, given the company's limited revenue and cash position relative to its operating losses, which may necessitate additional financing. As with all early-stage biotechnology companies, execution risk, regulatory uncertainty, and capital-market conditions are key factors that could affect the share price. This overview is informational and does not constitute investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations